0001610717-23-000412.txt : 20231219
0001610717-23-000412.hdr.sgml : 20231219
20231219195844
ACCESSION NUMBER: 0001610717-23-000412
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231217
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ogden Christopher
CENTRAL INDEX KEY: 0001914523
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 231499052
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD., SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 273521219
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2023-12-17
0001501989
CytomX Therapeutics, Inc.
CTMX
0001914523
Ogden Christopher
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., SUITE 400
SOUTH SAN FRANCISCO
CA
94080
true
SVP, Finance and Accounting
false
Common Stock
2023-12-17
4
M
0
6875
0
A
50647
D
Performance Stock Units (PSUs)
2023-12-17
4
M
0
6875
0
D
Common Stock
6875
6875
D
Represents partial vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
Includes 30,466 restricted stock units.
Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2023.
Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
2023-12-19